BIT:1ROG • CH0012032048
The current stock price of 1ROG.MI is 370 EUR. Today 1ROG.MI is down by -1.07%. In the past month the price increased by 8.19%.
ChartMill assigns a technical rating of 4 / 10 to 1ROG.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1ROG.MI. 1ROG.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
On January 29, 2026 1ROG.MI reported an EPS of 8.36 and a revenue of 30.57B. The company missed EPS expectations (-5.46% surprise) and missed revenue expectations (-3.25% surprise).
For the next year, analysts expect an EPS growth of 7.31% and a revenue growth 2.76% for 1ROG.MI
Over the last trailing twelve months 1ROG.MI reported a non-GAAP Earnings per Share(EPS) of 21.56. The EPS increased by 3.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.01 | 184.842B | ||
| SAN | SANOFI | 9.01 | 184.817B | ||
| 1SAN | SANOFI | 9.01 | 184.6B | ||
| UNC | UCB SA | 24.27 | 49.211B | ||
| UCB | UCB SA | 24.27 | 49.133B | ||
| 1MRK | MERCK KGAA | 12.9 | 48.217B | ||
| MRK | MERCK KGAA | 13.04 | 47.587B | ||
| BAYN | BAYER AG-REG | 8.25 | 38.442B | ||
| 1BAYN | BAYER AG-REG | 8.36 | 38.422B | ||
| IPN | IPSEN | 12.48 | 12.848B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 15.87 | 9.733B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.681B | ||
| VIRP | VIRBAC SA | 15.37 | 2.806B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
IPO: 2001-05-04
ROCHE HOLDING AG-GENUSSCHEIN
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
The current stock price of 1ROG.MI is 370 EUR. The price decreased by -1.07% in the last trading session.
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a dividend yield of 2.7%. The yearly dividend amount is currently 11.07.
1ROG.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) is 17.16. This is based on the reported non-GAAP earnings per share of 21.56 and the current share price of 370 EUR.
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a market capitalization of 299.42B EUR. This makes 1ROG.MI a Mega Cap stock.
You can find the ownership structure of ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) on the Ownership tab.